[唑来膦酸治疗骨质疏松症的疗效:国外研究证据]

Clinical calcium Pub Date : 2017-01-01
Daisuke Inoue
{"title":"[唑来膦酸治疗骨质疏松症的疗效:国外研究证据]","authors":"Daisuke Inoue","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Zoledronic acid is a nitrogen-containing bisphosphonate that has the strongest and the most persistent anti-resorptive activity. Once-yearly zoledronic acid has recently been approved for the treatment of osteoporosis in Japan. This overview summarizes abundant evidence of zoledronic acid, obtained from studies abroad, for its efficacy for postmenopausal, male and glucocorticoid-induced osteoporosis.</p>","PeriodicalId":502100,"journal":{"name":"Clinical calcium","volume":"27 2","pages":"247-255"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Efficacy of zoledronic acid for osteoporosis:evidence from studies abroad.]\",\"authors\":\"Daisuke Inoue\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Zoledronic acid is a nitrogen-containing bisphosphonate that has the strongest and the most persistent anti-resorptive activity. Once-yearly zoledronic acid has recently been approved for the treatment of osteoporosis in Japan. This overview summarizes abundant evidence of zoledronic acid, obtained from studies abroad, for its efficacy for postmenopausal, male and glucocorticoid-induced osteoporosis.</p>\",\"PeriodicalId\":502100,\"journal\":{\"name\":\"Clinical calcium\",\"volume\":\"27 2\",\"pages\":\"247-255\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical calcium\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical calcium","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

唑来膦酸是一种含氮双膦酸盐,具有最强和最持久的抗吸收活性。在日本,每年一次的唑来膦酸最近被批准用于治疗骨质疏松症。本文综述了唑来膦酸对绝经后、男性和糖皮质激素所致骨质疏松症的疗效的大量国外研究证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Efficacy of zoledronic acid for osteoporosis:evidence from studies abroad.]

Zoledronic acid is a nitrogen-containing bisphosphonate that has the strongest and the most persistent anti-resorptive activity. Once-yearly zoledronic acid has recently been approved for the treatment of osteoporosis in Japan. This overview summarizes abundant evidence of zoledronic acid, obtained from studies abroad, for its efficacy for postmenopausal, male and glucocorticoid-induced osteoporosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信